Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937228 | 0.89 | GAA (0.62) | RXFP1PTGS1KMT2ARAB9AMEN1 | |
| SCHEMBL7323880 | 0.86 | PTGS1 (0.59) | TSHRCYP1A2CYP2D6CYP2C19RXFP1 | |
| SCHEMBL9129050 | 0.85 | TSHR (0.61) | TSHRCYP1A2CYP2D6CYP2C19ELANE | |
| SCHEMBL204144 | 0.84 | HSD17B10 (0.54) | TSHRCYP1A2CYP2D6CYP2C19RXFP1 | |
| SCHEMBL505555 | 0.83 | NPC1 (0.61) | TSHRCYP1A2CYP2D6CYP2C19ELANE | |
| SCHEMBL207099 | 0.82 | TSHR (0.52) | TSHRCYP1A2CYP2D6CYP2C19ELANE | |
| SCHEMBL4831188 | 0.79 | CYP1A2 (0.54) | TSHRCYP1A2CYP2D6CYP2C19RXFP1 | |
| SCHEMBL205252 | 0.77 | ALDH1A1 (0.67) | TSHRRXFP1KMT2ANPC1RAB9A | |
| SCHEMBL7034528 | 0.76 | TRPV1 (0.56) | TSHRCYP1A2CYP2D6CYP2C19RXFP1 | |
| SCHEMBL204780 | 0.76 | MKNK1 (0.54) | TSHRCYP1A2CYP2D6CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | TSHR 387/4885CYP1A2 642/4885CYP2D6 848/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | TSHR 365/4885CYP1A2 583/4885CYP2D6 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.